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Epstein-Barr virus (EBV) was the
first recognized human tumor virus,
but it is not the causative agent for the
tumor in which it was discovered,
Burkitt lymphoma. Common to all
Burkitt lymphomas, endemic or spo-
radic, are distinctive chromosomal
translocations that reactivate expres-
sion of the c-myc protooncogene and
comprise the primary oncogenic
mechanism.
EBV is at least a contributory
cofactor in endemic Burkitt lym-
phoma, but the virus is detected in
<20% of sporadic cases in the United
States. EBV does cause infectious
mononucleosis, hairy leukoplakia,
and B-lymphoproliferative neoplasms
in immunocompromised persons. In
addition, the early and utterly consis-
tent presence of monoclonal EBV epi-
somes in nasopharyngeal carcinoma
worldwide suggests a crucial role for
the virus in that neoplasm. While tan-
talizing, associations with other dis-
eases, well reviewed in this volume,
are inconsistent and suggest that the
virus may have another role beyond
the etiologic, namely, by affecting the
phenotype of already existing tumor
cells and possibly propelling tumor
progression.
This book is assembled mostly
from a clinical perspective, and useful
chapters on several of the EBV dis-
eases bring together information not
easily found elsewhere. Well-
informed chapters on the virology and
epidemiology of EBV infection are
also included. One of the editors
(whose list of milestones displays the
clinical emphasis of the book) has
provided a nice historical summary. 
As is usual with such compila-
tions, the editors leave it to the con-
tributors to speak for themselves, and
the quality of the chapters is uneven.
Some fall short in citation of primary
sources or favor the author’s view
rather than one that weighs all the evi-
dence. Withal it is a useful book, and
having the less often discussed associ-
ations such as T-cell lymphomas and
leiomyosarcomas assigned a place
alongside authoritative chapters on
the classic associations, nasopharyn-
geal carcinoma and Burkitt lym-
phoma, is convenient. The volume
ends with a chapter on an EBV vac-
cine, which remains elusive after
many years. In contrast, the penulti-
mate chapter includes a brief summa-
ry of some successes with adoptive
immunotherapy for posttransplant
lymphoproliferative disease, which is
generally refractory to conventional
treatment. This volume is worth hav-
ing for the cross-section of knowledge
and developments in the EBV field it
presents.
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The purpose of this book is to
make the science of epidemic diseases
accessible and understandable; to
guide the general reader through the
maze of contagious diseases, their
past importance, the means by which
we came to understand them, and how
they may affect our future. This com-
mentary on general and disease-spe-
cific concerns covers the nature of
plagues; plagues, the price of being
sedentary (an evolutionary view); 6
plagues of antiquity (urinary schisto-
somiasis, the plague of Athens, malar-
ia in Rome, the Antonine plague, the
plagues of Cyprian and Justinian);
bubonic plague; AIDS (including a
history of virology and an account of
leukocyte function); typhus; malaria
(plus an explanation of sickle cell dis-
ease and genetics); cholera; smallpox;
preventing plagues (the immune sys-
tem, with a coda on vaccine develop-
ment); the plague protectors (antisep-
sis and antimicrobial drugs); syphilis;
tuberculosis; leprosy; 6 plagues of
Africa (sleeping sickness, river blind-
ness, guinea worm, yellow fever,
malaria, and hookworm) with the his-
tory of exploration and exploitation of
this continent; plagues without germs
(pellagra, beriberi, scurvy, and rick-
ets); and emerging plagues (rodent-
borne, West Nile virus, bovine
spongiform encephalopathy and
Creutzfeldt-Jakob disease, and
influenza). The text covers not only
the geography, history, microbiology,
and physiology of these infections but
also their influence on plastic art,
movies, literature, and music (with a
special fondness for nursery rhymes).BOOKS & MEDIA
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Surprisingly, the role of contempo-
rary epidemiologic methods and gov-
ernmental institutions is not exam-
ined. No explanation is included of
how present-day public health offi-
cials go about detecting a problem,
how they define an epidemic, how
they use data such as incidence or
attack rates to identify the cause, and
how laws and regulations (e.g., vac-
cine requirements for school entry
and rules for production of food and
biological materials) are indispensa-
ble for disease prevention. The text
would have profited from another
round of editing to modify overly
forceful generalizations, tighten the
discussion, and check for historical
and medical accuracy. For example,
acyclovir is not AZT, and AZT was
not available for first-line treatment of
AIDS in the early 1980s; cholera is
not slowly creeping into the Western
Hemisphere, but it produced large
epidemics in Central and South
America in the 1990s; Figure 9.7B is
not an antivaccination statement from
Boston in 1902 but, as the engraving
itself indicates, a provaccine state-
ment from England in 1898; vaccina-
tion with Mycobacterium bovis BCG
does not cause the tuberculin test
result to be negative; and malaria con-
trol efforts in the United States were
not interrupted by World War II but,
on the contrary, were enhanced by the
creation of an agency called Malaria
Control in War Areas.
This is a concise and clear account
of the biologic and historical determi-
nants of epidemic diseases. It is
marred by a small number of factual
errors and a failure to include epi-
demiologic and public health methods
as components of the equation that
determines the power of plagues.
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This book offers advanced treat-
ment of a broad selection of topics in
molecular medical mycology
authored by leading investigators. It
assumes a foundation of knowledge
of mycotic pathogens and is suitable
for the reader who is well-grounded in
molecular microbiology. It is highly
recommended for investigators plan-
ning to conduct medical mycology
research. The book is divided into 5
sections: General Principles, Model
Systems, Specific Pathogens, The
Host, and Future Directions. Only
selected highlights are described here
because of space limitations. 
The book reviews the development
of transforming and gene-silencing
methods for identifying virulence
determinants. An overview of
Candida albicans virulence under-
lines that molecular subtyping has
elucidated 3 major clades, which dif-
fer in their potential for producing
superficial versus deep-seated infec-
tion. The first step in pathogenesis is
adherence to host tissues. The
endothelial and epithelial specificity
of members of the C. albicans Als
family of adherence molecules is
defined by the adherence profile of
null mutants. The discovery through
the genome sequence of C. albicans
mating type locus and the delineation
of the unique pathway of a parasexual
cycle are discussed. Although the
population is largely clonal and seems
locked in a diploid state, the species
has a demonstrated ability to undergo
recombination. 
The phylogenetic species concept
has led to a better understanding of
the lineage of pathogenic fungi, espe-
cially for the mitosporic fungi, which
have no known sexual stage. The evo-
lution of fungal species, shown by
multilocus sequence typing, enabled
construction of a phylogenetic tree of
all known fungal pathogens with
assignments to well-described fami-
lies and orders. 
Mechanisms of resistance to anti-
fungal agents are discussed, including
insights from genome sequence
analysis and recent clinical observa-
tions such as the role of transcription
factors in upregulating efflux pumps
in the presence of antifungal agents or
steroids. How environmental fungi
have acquired their pathogenic poten-
tial for humans, even those whose
immune function is intact, is a puzzle,
but clues come from the interaction of
fungi with soil-dwelling amebae.
Fungi escape endocytosis by convert-
ing from yeast to hyphal forms; this
not only conditions them for intracel-
lular survival but also suggests how
dimorphism may have originated.
Transcriptional profiling using
microarrays is a powerful tool for
identifying genes expressed during
mold-to-yeast morphogenesis and
host-fungus interactions in infected
tissue cultures and biofilms.
Interspersed in the book are examples
of exploiting this technology to dis-
cover key regulatory pathways. 
No subject attracts more interest,
yet is strewn with more pitfalls, than